Selected research
Market Outlook & Growth Opportunities
Global Pediatric CAR T-cell Therapy Market Outlook and Growth Opportunities 2026
Market perspective
The global Pediatric CAR T-cell Therapy market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.
The North America market for Pediatric CAR T-cell Therapy is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Pediatric CAR T-cell Therapy is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Pediatric CAR T-cell Therapy is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
In China, the Pediatric CAR T-cell Therapy market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Major global companies in the Pediatric CAR T-cell Therapy market include Bristol Myers Squibb，BMS, Johnson & Johnson, Gilead Sciences, Novartis, JW Therapeutics, Imunopharm Technology Co., Ltd., CARsgen Therapeutics and Cartesian Therapeutics, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.
This report provides an overview of the global Pediatric CAR T-cell Therapy market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Pediatric CAR T-cell Therapy and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Pediatric CAR T-cell Therapy revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Pediatric CAR T-cell Therapy market.
Pediatric CAR T-cell Therapy Segment by Company
Bristol Myers Squibb，BMS
Johnson & Johnson
Gilead Sciences
Novartis
JW Therapeutics
Imunopharm Technology Co., Ltd.
CARsgen Therapeutics
Cartesian Therapeutics
Pediatric CAR T-cell Therapy Segment by Type
CD19
BCMA
Others
Pediatric CAR T-cell Therapy Segment by Application
Multiple Myeloma
B-Cell Lymphoma (BCL)
Acute Lymphoblastic Leukemia (ALL)
Others
Pediatric CAR T-cell Therapy Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global Pediatric CAR T-cell Therapy status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the Pediatric CAR T-cell Therapy key companies, revenue, market share, and recent developments.
3. To split the Pediatric CAR T-cell Therapy breakdown data by regions, type, companies, and application.
4. To analyze the global and key regions Pediatric CAR T-cell Therapy market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Pediatric CAR T-cell Therapy significant trends, drivers, influence factors in global and regions.
6. To analyze Pediatric CAR T-cell Therapy competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pediatric CAR T-cell Therapy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Pediatric CAR T-cell Therapy and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pediatric CAR T-cell Therapy.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Pediatric CAR T-cell Therapy industry.
Chapter 3: Detailed analysis of Pediatric CAR T-cell Therapy company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales value of Pediatric CAR T-cell Therapy in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.
Chapter 7: Sales value of Pediatric CAR T-cell Therapy in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 9: Concluding Insights.
More report detail
Tables and figures
List of Tables
Table 1. Pediatric CAR T-cell Therapy Industry Trends
Table 2. Pediatric CAR T-cell Therapy Industry Drivers
Table 3. Pediatric CAR T-cell Therapy Industry Opportunities and Challenges
Table 4. Pediatric CAR T-cell Therapy Industry Restraints
Table 5. Global Pediatric CAR T-cell Therapy Revenue by Company (US$ Million) & (2021-2026)
Table 6. Global Pediatric CAR T-cell Therapy Revenue Share by Company (2021-2026)
Table 7. Global Pediatric CAR T-cell Therapy Company Ranking, (2024-2026) & (US$ Million)
Table 8. Global Pediatric CAR T-cell Therapy Key Company Manufacturing Base & Headquarters
Table 9. Global Pediatric CAR T-cell Therapy Company, Product Type & Application
Table 10. Global Pediatric CAR T-cell Therapy Company Establishment Date
Table 11. Global Company Market Concentration Ratio (CR5 and HHI)
Table 12. Global Pediatric CAR T-cell Therapy by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025)
Table 13. Mergers & Acquisitions, Expansion
Table 14. Significant Companies of CD19
Table 15. Significant Companies of BCMA
Table 16. Significant Companies of Others
Table 17. Global Pediatric CAR T-cell Therapy Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million)
Table 18. Global Pediatric CAR T-cell Therapy Sales Value by Type (2021-2026) & (US$ Million)
Table 19. Global Pediatric CAR T-cell Therapy Sales Value by Type (2027-2032) & (US$ Million)
Table 20. Global Pediatric CAR T-cell Therapy Sales Value Share by Type (2021-2026)
Table 21. Global Pediatric CAR T-cell Therapy Sales Value Share by Type (2027-2032)
Table 22. Significant Companies of Multiple Myeloma
Table 23. Significant Companies of B-Cell Lymphoma (BCL)
Table 24. Significant Companies of Acute Lymphoblastic Leukemia (ALL)
Table 25. Significant Companies of Others
Table 26. Global Pediatric CAR T-cell Therapy Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million)
Table 27. Global Pediatric CAR T-cell Therapy Sales Value by Application (2021-2026) & (US$ Million)
Table 28. Global Pediatric CAR T-cell Therapy Sales Value by Application (2027-2032) & (US$ Million)
Table 29. Global Pediatric CAR T-cell Therapy Sales Value Share by Application (2021-2026)
Table 30. Global Pediatric CAR T-cell Therapy Sales Value Share by Application (2027-2032)
Table 31. Global Pediatric CAR T-cell Therapy Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million)
Table 32. Global Pediatric CAR T-cell Therapy Sales Value by Region (2021-2026) & (US$ Million)
Table 33. Global Pediatric CAR T-cell Therapy Sales Value Share by Region (2021-2026)
Table 34. Global Pediatric CAR T-cell Therapy Sales Value by Region (2027-2032) & (US$ Million)
Table 35. Global Pediatric CAR T-cell Therapy Sales Value Share by Region (2027-2032)
Table 36. Global Pediatric CAR T-cell Therapy Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 37. Global Pediatric CAR T-cell Therapy Sales Value by Country (2021-2026) & (US$ Million)
Table 38. Global Pediatric CAR T-cell Therapy Sales Value Market Share by Country (2021-2026)
Table 39. Global Pediatric CAR T-cell Therapy Sales Value by Country (2027-2032) & (US$ Million)
Table 40. Global Pediatric CAR T-cell Therapy Sales Value Market Share by Country (2027-2032)
Table 41. Bristol Myers Squibb，BMS Company Information
Table 42. Bristol Myers Squibb，BMS Business Overview
Table 43. Bristol Myers Squibb，BMS Pediatric CAR T-cell Therapy Revenue (US$ Million) and Gross Margin (2021-2026)
Table 44. Bristol Myers Squibb，BMS Pediatric CAR T-cell Therapy Product Portfolio
Table 45. Bristol Myers Squibb，BMS Recent Development
Table 46. Johnson & Johnson Company Information
Table 47. Johnson & Johnson Business Overview
Table 48. Johnson & Johnson Pediatric CAR T-cell Therapy Revenue (US$ Million) and Gross Margin (2021-2026)
Table 49. Johnson & Johnson Pediatric CAR T-cell Therapy Product Portfolio
Table 50. Johnson & Johnson Recent Development
Table 51. Gilead Sciences Company Information
Table 52. Gilead Sciences Business Overview
Table 53. Gilead Sciences Pediatric CAR T-cell Therapy Revenue (US$ Million) and Gross Margin (2021-2026)
Table 54. Gilead Sciences Pediatric CAR T-cell Therapy Product Portfolio
Table 55. Gilead Sciences Recent Development
Table 56. Novartis Company Information
Table 57. Novartis Business Overview
Table 58. Novartis Pediatric CAR T-cell Therapy Revenue (US$ Million) and Gross Margin (2021-2026)
Table 59. Novartis Pediatric CAR T-cell Therapy Product Portfolio
Table 60. Novartis Recent Development
Table 61. JW Therapeutics Company Information
Table 62. JW Therapeutics Business Overview
Table 63. JW Therapeutics Pediatric CAR T-cell Therapy Revenue (US$ Million) and Gross Margin (2021-2026)
Table 64. JW Therapeutics Pediatric CAR T-cell Therapy Product Portfolio
Table 65. JW Therapeutics Recent Development
Table 66. Imunopharm Technology Co., Ltd. Company Information
Table 67. Imunopharm Technology Co., Ltd. Business Overview
Table 68. Imunopharm Technology Co., Ltd. Pediatric CAR T-cell Therapy Revenue (US$ Million) and Gross Margin (2021-2026)
Table 69. Imunopharm Technology Co., Ltd. Pediatric CAR T-cell Therapy Product Portfolio
Table 70. Imunopharm Technology Co., Ltd. Recent Development
Table 71. CARsgen Therapeutics Company Information
Table 72. CARsgen Therapeutics Business Overview
Table 73. CARsgen Therapeutics Pediatric CAR T-cell Therapy Revenue (US$ Million) and Gross Margin (2021-2026)
Table 74. CARsgen Therapeutics Pediatric CAR T-cell Therapy Product Portfolio
Table 75. CARsgen Therapeutics Recent Development
Table 76. Cartesian Therapeutics Company Information
Table 77. Cartesian Therapeutics Business Overview
Table 78. Cartesian Therapeutics Pediatric CAR T-cell Therapy Revenue (US$ Million) and Gross Margin (2021-2026)
Table 79. Cartesian Therapeutics Pediatric CAR T-cell Therapy Product Portfolio
Table 80. Cartesian Therapeutics Recent Development
Table 81. Research Programs/Design for This Report
Table 82. Authors List of This Report
Table 83. Secondary Sources
Table 84. Primary Sources
List of Figures
Figure 1. Pediatric CAR T-cell Therapy Product Image
Figure 2. Global Pediatric CAR T-cell Therapy Market Size (US$ Million), 2021 VS 2025 VS 2032
Figure 3. Global Pediatric CAR T-cell Therapy Market Size (2021-2032) & (US$ Million)
Figure 4. Global Pediatric CAR T-cell Therapy Company Revenue Ranking in 2025 (US$ Million)
Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million)
Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025
Figure 7. CD19 Image
Figure 8. BCMA Image
Figure 9. Others Image
Figure 10. Global Pediatric CAR T-cell Therapy Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million)
Figure 11. Global Pediatric CAR T-cell Therapy Sales Value Share 2021 VS 2025 VS 2032
Figure 12. Global Pediatric CAR T-cell Therapy Sales Value Share by Type (2021-2032)
Figure 13. Multiple Myeloma Image
Figure 14. B-Cell Lymphoma (BCL) Image
Figure 15. Acute Lymphoblastic Leukemia (ALL) Image
Figure 16. Others Image
Figure 17. Global Pediatric CAR T-cell Therapy Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million)
Figure 18. Global Pediatric CAR T-cell Therapy Sales Value Share 2021 VS 2025 VS 2032
Figure 19. Global Pediatric CAR T-cell Therapy Sales Value Share by Application (2021-2032)
Figure 20. Global Pediatric CAR T-cell Therapy Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million)
Figure 21. Global Pediatric CAR T-cell Therapy Sales Value Share by Region: 2021 VS 2025 VS 2032
Figure 22. North America Pediatric CAR T-cell Therapy Sales Value (2021-2032) & (US$ Million)
Figure 23. North America Pediatric CAR T-cell Therapy Sales Value Share by Country (%), 2025 VS 2032
Figure 24. Europe Pediatric CAR T-cell Therapy Sales Value (2021-2032) & (US$ Million)
Figure 25. Europe Pediatric CAR T-cell Therapy Sales Value Share by Country (%), 2025 VS 2032
Figure 26. Asia-Pacific Pediatric CAR T-cell Therapy Sales Value (2021-2032) & (US$ Million)
Figure 27. Asia-Pacific Pediatric CAR T-cell Therapy Sales Value Share by Country (%), 2025 VS 2032
Figure 28. South America Pediatric CAR T-cell Therapy Sales Value (2021-2032) & (US$ Million)
Figure 29. South America Pediatric CAR T-cell Therapy Sales Value Share by Country (%), 2025 VS 2032
Figure 30. Middle East & Africa Pediatric CAR T-cell Therapy Sales Value (2021-2032) & (US$ Million)
Figure 31. Middle East & Africa Pediatric CAR T-cell Therapy Sales Value Share by Country (%), 2025 VS 2032
Figure 32. USA Pediatric CAR T-cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 33. USA Pediatric CAR T-cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 34. USA Pediatric CAR T-cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 35. Canada Pediatric CAR T-cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 36. Canada Pediatric CAR T-cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 37. Canada Pediatric CAR T-cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 38. Mexico Pediatric CAR T-cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 39. Mexico Pediatric CAR T-cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 40. Mexico Pediatric CAR T-cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 41. Germany Pediatric CAR T-cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 42. Germany Pediatric CAR T-cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 43. Germany Pediatric CAR T-cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 44. France Pediatric CAR T-cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 45. France Pediatric CAR T-cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 46. France Pediatric CAR T-cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 47. U.K. Pediatric CAR T-cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 48. U.K. Pediatric CAR T-cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 49. U.K. Pediatric CAR T-cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 50. Italy Pediatric CAR T-cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 51. Italy Pediatric CAR T-cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 52. Italy Pediatric CAR T-cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 53. Spain Pediatric CAR T-cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 54. Spain Pediatric CAR T-cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 55. Spain Pediatric CAR T-cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 56. Russia Pediatric CAR T-cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 57. Russia Pediatric CAR T-cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 58. Russia Pediatric CAR T-cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 59. Netherlands Pediatric CAR T-cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 60. Netherlands Pediatric CAR T-cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 61. Netherlands Pediatric CAR T-cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 62. Nordic Countries Pediatric CAR T-cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 63. Nordic Countries Pediatric CAR T-cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 64. Nordic Countries Pediatric CAR T-cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 65. China Pediatric CAR T-cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 66. China Pediatric CAR T-cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 67. China Pediatric CAR T-cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 68. Japan Pediatric CAR T-cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 69. Japan Pediatric CAR T-cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 70. Japan Pediatric CAR T-cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 71. South Korea Pediatric CAR T-cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 72. South Korea Pediatric CAR T-cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 73. South Korea Pediatric CAR T-cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 74. India Pediatric CAR T-cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 75. India Pediatric CAR T-cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 76. India Pediatric CAR T-cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 77. Australia Pediatric CAR T-cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 78. Australia Pediatric CAR T-cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 79. Australia Pediatric CAR T-cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 80. Southeast Asia Pediatric CAR T-cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 81. Southeast Asia Pediatric CAR T-cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 82. Southeast Asia Pediatric CAR T-cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 83. Brazil Pediatric CAR T-cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 84. Brazil Pediatric CAR T-cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 85. Brazil Pediatric CAR T-cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 86. Argentina Pediatric CAR T-cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 87. Argentina Pediatric CAR T-cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 88. Argentina Pediatric CAR T-cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 89. Chile Pediatric CAR T-cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 90. Chile Pediatric CAR T-cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 91. Chile Pediatric CAR T-cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 92. Colombia Pediatric CAR T-cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 93. Colombia Pediatric CAR T-cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 94. Colombia Pediatric CAR T-cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 95. Peru Pediatric CAR T-cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 96. Peru Pediatric CAR T-cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 97. Peru Pediatric CAR T-cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 98. Saudi Arabia Pediatric CAR T-cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 99. Saudi Arabia Pediatric CAR T-cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 100. Saudi Arabia Pediatric CAR T-cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 101. Israel Pediatric CAR T-cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 102. Israel Pediatric CAR T-cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 103. Israel Pediatric CAR T-cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 104. UAE Pediatric CAR T-cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 105. UAE Pediatric CAR T-cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 106. UAE Pediatric CAR T-cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 107. Turkey Pediatric CAR T-cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 108. Turkey Pediatric CAR T-cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 109. Turkey Pediatric CAR T-cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 110. Iran Pediatric CAR T-cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 111. Iran Pediatric CAR T-cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 112. Iran Pediatric CAR T-cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 113. Egypt Pediatric CAR T-cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 114. Egypt Pediatric CAR T-cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 115. Egypt Pediatric CAR T-cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 116. Years Considered
Figure 117. Research Process
Figure 118. Key Executives Interviewed
Scope & coverage.
Types
- CD19
- BCMA
- Others
Applications
- Multiple Myeloma
- B-Cell Lymphoma (BCL)
- Acute Lymphoblastic Leukemia (ALL)
- Others
Companies covered
- Bristol Myers Squibb，BMS
- Johnson & Johnson
- Gilead Sciences
- Novartis
- JW Therapeutics
- Imunopharm Technology Co., Ltd.
- CARsgen Therapeutics
- Cartesian Therapeutics
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Pediatric CAR T-cell Therapy Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Pediatric CAR T-cell Therapy Market Size (2021-2032)
- 1.4 Assumptions and Limitations
- 1.5 Study Goals and Objectives
2 Pediatric CAR T-cell Therapy Market Dynamics
- 2.1 Pediatric CAR T-cell Therapy Industry Trends
- 2.2 Pediatric CAR T-cell Therapy Industry Drivers
- 2.3 Pediatric CAR T-cell Therapy Industry Opportunities and Challenges
- 2.4 Pediatric CAR T-cell Therapy Industry Restraints
3 Pediatric CAR T-cell Therapy Market by Company
- 3.1 Global Pediatric CAR T-cell Therapy Company Revenue Ranking in 2025
- 3.2 Global Pediatric CAR T-cell Therapy Revenue by Company (2021-2026)
- 3.3 Global Pediatric CAR T-cell Therapy Company Ranking (2024-2026)
- 3.4 Global Pediatric CAR T-cell Therapy Company Manufacturing Base and Headquarters
- 3.5 Global Pediatric CAR T-cell Therapy Company Product Type and Application
- 3.6 Global Pediatric CAR T-cell Therapy Company Establishment Date
- 3.7 Market Competitive Analysis
- 3.7.1 Global Pediatric CAR T-cell Therapy Market Concentration Ratio (CR5 and HHI)
- 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
- 3.7.3 2025 Pediatric CAR T-cell Therapy Tier 1, Tier 2, and Tier 3 Companies
- 3.8 Mergers and Acquisitions Expansion
4 Pediatric CAR T-cell Therapy Market by Type
- 4.1 Pediatric CAR T-cell Therapy Type Introduction
- 4.1.1 CD19
- 4.1.2 BCMA
- 4.1.3 Others
- 4.2 Global Pediatric CAR T-cell Therapy Sales Value by Type
- 4.2.1 Global Pediatric CAR T-cell Therapy Sales Value by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Pediatric CAR T-cell Therapy Sales Value by Type (2021-2032)
- 4.2.3 Global Pediatric CAR T-cell Therapy Sales Value Share by Type (2021-2032)
5 Pediatric CAR T-cell Therapy Market by Application
- 5.1 Pediatric CAR T-cell Therapy Application Introduction
- 5.1.1 Multiple Myeloma
- 5.1.2 B-Cell Lymphoma (BCL)
- 5.1.3 Acute Lymphoblastic Leukemia (ALL)
- 5.1.4 Others
- 5.2 Global Pediatric CAR T-cell Therapy Sales Value by Application
- 5.2.1 Global Pediatric CAR T-cell Therapy Sales Value by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Pediatric CAR T-cell Therapy Sales Value by Application (2021-2032)
- 5.2.3 Global Pediatric CAR T-cell Therapy Sales Value Share by Application (2021-2032)
6 Pediatric CAR T-cell Therapy Regional Value Analysis
- 6.1 Global Pediatric CAR T-cell Therapy Sales Value by Region: 2021 VS 2025 VS 2032
- 6.2 Global Pediatric CAR T-cell Therapy Sales Value by Region (2021-2032)
- 6.2.1 Global Pediatric CAR T-cell Therapy Sales Value by Region: 2021-2026
- 6.2.2 Global Pediatric CAR T-cell Therapy Sales Value by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Pediatric CAR T-cell Therapy Sales Value (2021-2032)
- 6.3.2 North America Pediatric CAR T-cell Therapy Sales Value Share by Country, 2025 VS 2032
- 6.4 Europe
- 6.4.1 Europe Pediatric CAR T-cell Therapy Sales Value (2021-2032)
- 6.4.2 Europe Pediatric CAR T-cell Therapy Sales Value Share by Country, 2025 VS 2032
- 6.5 Asia-Pacific
- 6.5.1 Asia-Pacific Pediatric CAR T-cell Therapy Sales Value (2021-2032)
- 6.5.2 Asia-Pacific Pediatric CAR T-cell Therapy Sales Value Share by Country, 2025 VS 2032
- 6.6 South America
- 6.6.1 South America Pediatric CAR T-cell Therapy Sales Value (2021-2032)
- 6.6.2 South America Pediatric CAR T-cell Therapy Sales Value Share by Country, 2025 VS 2032
- 6.7 Middle East & Africa
- 6.7.1 Middle East & Africa Pediatric CAR T-cell Therapy Sales Value (2021-2032)
- 6.7.2 Middle East & Africa Pediatric CAR T-cell Therapy Sales Value Share by Country, 2025 VS 2032
7 Pediatric CAR T-cell Therapy Country-level Value Analysis
- 7.1 Global Pediatric CAR T-cell Therapy Sales Value by Country: 2021 VS 2025 VS 2032
- 7.2 Global Pediatric CAR T-cell Therapy Sales Value by Country (2021-2032)
- 7.2.1 Global Pediatric CAR T-cell Therapy Sales Value by Country (2021-2026)
- 7.2.2 Global Pediatric CAR T-cell Therapy Sales Value by Country (2027-2032)
- 7.3 USA
- 7.3.1 USA Pediatric CAR T-cell Therapy Sales Value Growth Rate (2021-2032)
- 7.3.2 USA Pediatric CAR T-cell Therapy Sales Value Share by Type, 2025 VS 2032
- 7.3.3 USA Pediatric CAR T-cell Therapy Sales Value Share by Application, 2025 VS 2032
- 7.4 Canada
- 7.4.1 Canada Pediatric CAR T-cell Therapy Sales Value Growth Rate (2021-2032)
- 7.4.2 Canada Pediatric CAR T-cell Therapy Sales Value Share by Type, 2025 VS 2032
- 7.4.3 Canada Pediatric CAR T-cell Therapy Sales Value Share by Application, 2025 VS 2032
- 7.5 Mexico
- 7.5.1 Mexico Pediatric CAR T-cell Therapy Sales Value Growth Rate (2021-2032)
- 7.5.2 Mexico Pediatric CAR T-cell Therapy Sales Value Share by Type, 2025 VS 2032
- 7.5.3 Mexico Pediatric CAR T-cell Therapy Sales Value Share by Application, 2025 VS 2032
- 7.6 Germany
- 7.6.1 Germany Pediatric CAR T-cell Therapy Sales Value Growth Rate (2021-2032)
- 7.6.2 Germany Pediatric CAR T-cell Therapy Sales Value Share by Type, 2025 VS 2032
- 7.6.3 Germany Pediatric CAR T-cell Therapy Sales Value Share by Application, 2025 VS 2032
- 7.7 France
- 7.7.1 France Pediatric CAR T-cell Therapy Sales Value Growth Rate (2021-2032)
- 7.7.2 France Pediatric CAR T-cell Therapy Sales Value Share by Type, 2025 VS 2032
- 7.7.3 France Pediatric CAR T-cell Therapy Sales Value Share by Application, 2025 VS 2032
- 7.8 U.K.
- 7.8.1 U.K. Pediatric CAR T-cell Therapy Sales Value Growth Rate (2021-2032)
- 7.8.2 U.K. Pediatric CAR T-cell Therapy Sales Value Share by Type, 2025 VS 2032
- 7.8.3 U.K. Pediatric CAR T-cell Therapy Sales Value Share by Application, 2025 VS 2032
- 7.9 Italy
- 7.9.1 Italy Pediatric CAR T-cell Therapy Sales Value Growth Rate (2021-2032)
- 7.9.2 Italy Pediatric CAR T-cell Therapy Sales Value Share by Type, 2025 VS 2032
- 7.9.3 Italy Pediatric CAR T-cell Therapy Sales Value Share by Application, 2025 VS 2032
- 7.10 Spain
- 7.10.1 Spain Pediatric CAR T-cell Therapy Sales Value Growth Rate (2021-2032)
- 7.10.2 Spain Pediatric CAR T-cell Therapy Sales Value Share by Type, 2025 VS 2032
- 7.10.3 Spain Pediatric CAR T-cell Therapy Sales Value Share by Application, 2025 VS 2032
- 7.11 Russia
- 7.11.1 Russia Pediatric CAR T-cell Therapy Sales Value Growth Rate (2021-2032)
- 7.11.2 Russia Pediatric CAR T-cell Therapy Sales Value Share by Type, 2025 VS 2032
- 7.11.3 Russia Pediatric CAR T-cell Therapy Sales Value Share by Application, 2025 VS 2032
- 7.12 Netherlands
- 7.12.1 Netherlands Pediatric CAR T-cell Therapy Sales Value Growth Rate (2021-2032)
- 7.12.2 Netherlands Pediatric CAR T-cell Therapy Sales Value Share by Type, 2025 VS 2032
- 7.12.3 Netherlands Pediatric CAR T-cell Therapy Sales Value Share by Application, 2025 VS 2032
- 7.13 Nordic Countries
- 7.13.1 Nordic Countries Pediatric CAR T-cell Therapy Sales Value Growth Rate (2021-2032)
- 7.13.2 Nordic Countries Pediatric CAR T-cell Therapy Sales Value Share by Type, 2025 VS 2032
- 7.13.3 Nordic Countries Pediatric CAR T-cell Therapy Sales Value Share by Application, 2025 VS 2032
- 7.14 China
- 7.14.1 China Pediatric CAR T-cell Therapy Sales Value Growth Rate (2021-2032)
- 7.14.2 China Pediatric CAR T-cell Therapy Sales Value Share by Type, 2025 VS 2032
- 7.14.3 China Pediatric CAR T-cell Therapy Sales Value Share by Application, 2025 VS 2032
- 7.15 Japan
- 7.15.1 Japan Pediatric CAR T-cell Therapy Sales Value Growth Rate (2021-2032)
- 7.15.2 Japan Pediatric CAR T-cell Therapy Sales Value Share by Type, 2025 VS 2032
- 7.15.3 Japan Pediatric CAR T-cell Therapy Sales Value Share by Application, 2025 VS 2032
- 7.16 South Korea
- 7.16.1 South Korea Pediatric CAR T-cell Therapy Sales Value Growth Rate (2021-2032)
- 7.16.2 South Korea Pediatric CAR T-cell Therapy Sales Value Share by Type, 2025 VS 2032
- 7.16.3 South Korea Pediatric CAR T-cell Therapy Sales Value Share by Application, 2025 VS 2032
- 7.17 India
- 7.17.1 India Pediatric CAR T-cell Therapy Sales Value Growth Rate (2021-2032)
- 7.17.2 India Pediatric CAR T-cell Therapy Sales Value Share by Type, 2025 VS 2032
- 7.17.3 India Pediatric CAR T-cell Therapy Sales Value Share by Application, 2025 VS 2032
- 7.18 Australia
- 7.18.1 Australia Pediatric CAR T-cell Therapy Sales Value Growth Rate (2021-2032)
- 7.18.2 Australia Pediatric CAR T-cell Therapy Sales Value Share by Type, 2025 VS 2032
- 7.18.3 Australia Pediatric CAR T-cell Therapy Sales Value Share by Application, 2025 VS 2032
- 7.19 Southeast Asia
- 7.19.1 Southeast Asia Pediatric CAR T-cell Therapy Sales Value Growth Rate (2021-2032)
- 7.19.2 Southeast Asia Pediatric CAR T-cell Therapy Sales Value Share by Type, 2025 VS 2032
- 7.19.3 Southeast Asia Pediatric CAR T-cell Therapy Sales Value Share by Application, 2025 VS 2032
- 7.20 Brazil
- 7.20.1 Brazil Pediatric CAR T-cell Therapy Sales Value Growth Rate (2021-2032)
- 7.20.2 Brazil Pediatric CAR T-cell Therapy Sales Value Share by Type, 2025 VS 2032
- 7.20.3 Brazil Pediatric CAR T-cell Therapy Sales Value Share by Application, 2025 VS 2032
- 7.21 Argentina
- 7.21.1 Argentina Pediatric CAR T-cell Therapy Sales Value Growth Rate (2021-2032)
- 7.21.2 Argentina Pediatric CAR T-cell Therapy Sales Value Share by Type, 2025 VS 2032
- 7.21.3 Argentina Pediatric CAR T-cell Therapy Sales Value Share by Application, 2025 VS 2032
- 7.22 Chile
- 7.22.1 Chile Pediatric CAR T-cell Therapy Sales Value Growth Rate (2021-2032)
- 7.22.2 Chile Pediatric CAR T-cell Therapy Sales Value Share by Type, 2025 VS 2032
- 7.22.3 Chile Pediatric CAR T-cell Therapy Sales Value Share by Application, 2025 VS 2032
- 7.23 Colombia
- 7.23.1 Colombia Pediatric CAR T-cell Therapy Sales Value Growth Rate (2021-2032)
- 7.23.2 Colombia Pediatric CAR T-cell Therapy Sales Value Share by Type, 2025 VS 2032
- 7.23.3 Colombia Pediatric CAR T-cell Therapy Sales Value Share by Application, 2025 VS 2032
- 7.24 Peru
- 7.24.1 Peru Pediatric CAR T-cell Therapy Sales Value Growth Rate (2021-2032)
- 7.24.2 Peru Pediatric CAR T-cell Therapy Sales Value Share by Type, 2025 VS 2032
- 7.24.3 Peru Pediatric CAR T-cell Therapy Sales Value Share by Application, 2025 VS 2032
- 7.25 Saudi Arabia
- 7.25.1 Saudi Arabia Pediatric CAR T-cell Therapy Sales Value Growth Rate (2021-2032)
- 7.25.2 Saudi Arabia Pediatric CAR T-cell Therapy Sales Value Share by Type, 2025 VS 2032
- 7.25.3 Saudi Arabia Pediatric CAR T-cell Therapy Sales Value Share by Application, 2025 VS 2032
- 7.26 Israel
- 7.26.1 Israel Pediatric CAR T-cell Therapy Sales Value Growth Rate (2021-2032)
- 7.26.2 Israel Pediatric CAR T-cell Therapy Sales Value Share by Type, 2025 VS 2032
- 7.26.3 Israel Pediatric CAR T-cell Therapy Sales Value Share by Application, 2025 VS 2032
- 7.27 UAE
- 7.27.1 UAE Pediatric CAR T-cell Therapy Sales Value Growth Rate (2021-2032)
- 7.27.2 UAE Pediatric CAR T-cell Therapy Sales Value Share by Type, 2025 VS 2032
- 7.27.3 UAE Pediatric CAR T-cell Therapy Sales Value Share by Application, 2025 VS 2032
- 7.28 Turkey
- 7.28.1 Turkey Pediatric CAR T-cell Therapy Sales Value Growth Rate (2021-2032)
- 7.28.2 Turkey Pediatric CAR T-cell Therapy Sales Value Share by Type, 2025 VS 2032
- 7.28.3 Turkey Pediatric CAR T-cell Therapy Sales Value Share by Application, 2025 VS 2032
- 7.29 Iran
- 7.29.1 Iran Pediatric CAR T-cell Therapy Sales Value Growth Rate (2021-2032)
- 7.29.2 Iran Pediatric CAR T-cell Therapy Sales Value Share by Type, 2025 VS 2032
- 7.29.3 Iran Pediatric CAR T-cell Therapy Sales Value Share by Application, 2025 VS 2032
- 7.30 Egypt
- 7.30.1 Egypt Pediatric CAR T-cell Therapy Sales Value Growth Rate (2021-2032)
- 7.30.2 Egypt Pediatric CAR T-cell Therapy Sales Value Share by Type, 2025 VS 2032
- 7.30.3 Egypt Pediatric CAR T-cell Therapy Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
- 8.1 Bristol Myers Squibb，BMS
- 8.1.1 Bristol Myers Squibb，BMS Company Information
- 8.1.2 Bristol Myers Squibb，BMS Business Overview
- 8.1.3 Bristol Myers Squibb，BMS Pediatric CAR T-cell Therapy Revenue and Gross Margin (2021-2026)
- 8.1.4 Bristol Myers Squibb，BMS Pediatric CAR T-cell Therapy Product Portfolio
- 8.1.5 Bristol Myers Squibb，BMS Recent Developments
- 8.2 Johnson & Johnson
- 8.2.1 Johnson & Johnson Company Information
- 8.2.2 Johnson & Johnson Business Overview
- 8.2.3 Johnson & Johnson Pediatric CAR T-cell Therapy Revenue and Gross Margin (2021-2026)
- 8.2.4 Johnson & Johnson Pediatric CAR T-cell Therapy Product Portfolio
- 8.2.5 Johnson & Johnson Recent Developments
- 8.3 Gilead Sciences
- 8.3.1 Gilead Sciences Company Information
- 8.3.2 Gilead Sciences Business Overview
- 8.3.3 Gilead Sciences Pediatric CAR T-cell Therapy Revenue and Gross Margin (2021-2026)
- 8.3.4 Gilead Sciences Pediatric CAR T-cell Therapy Product Portfolio
- 8.3.5 Gilead Sciences Recent Developments
- 8.4 Novartis
- 8.4.1 Novartis Company Information
- 8.4.2 Novartis Business Overview
- 8.4.3 Novartis Pediatric CAR T-cell Therapy Revenue and Gross Margin (2021-2026)
- 8.4.4 Novartis Pediatric CAR T-cell Therapy Product Portfolio
- 8.4.5 Novartis Recent Developments
- 8.5 JW Therapeutics
- 8.5.1 JW Therapeutics Company Information
- 8.5.2 JW Therapeutics Business Overview
- 8.5.3 JW Therapeutics Pediatric CAR T-cell Therapy Revenue and Gross Margin (2021-2026)
- 8.5.4 JW Therapeutics Pediatric CAR T-cell Therapy Product Portfolio
- 8.5.5 JW Therapeutics Recent Developments
- 8.6 Imunopharm Technology Co., Ltd.
- 8.6.1 Imunopharm Technology Co., Ltd. Company Information
- 8.6.2 Imunopharm Technology Co., Ltd. Business Overview
- 8.6.3 Imunopharm Technology Co., Ltd. Pediatric CAR T-cell Therapy Revenue and Gross Margin (2021-2026)
- 8.6.4 Imunopharm Technology Co., Ltd. Pediatric CAR T-cell Therapy Product Portfolio
- 8.6.5 Imunopharm Technology Co., Ltd. Recent Developments
- 8.7 CARsgen Therapeutics
- 8.7.1 CARsgen Therapeutics Company Information
- 8.7.2 CARsgen Therapeutics Business Overview
- 8.7.3 CARsgen Therapeutics Pediatric CAR T-cell Therapy Revenue and Gross Margin (2021-2026)
- 8.7.4 CARsgen Therapeutics Pediatric CAR T-cell Therapy Product Portfolio
- 8.7.5 CARsgen Therapeutics Recent Developments
- 8.8 Cartesian Therapeutics
- 8.8.1 Cartesian Therapeutics Company Information
- 8.8.2 Cartesian Therapeutics Business Overview
- 8.8.3 Cartesian Therapeutics Pediatric CAR T-cell Therapy Revenue and Gross Margin (2021-2026)
- 8.8.4 Cartesian Therapeutics Pediatric CAR T-cell Therapy Product Portfolio
- 8.8.5 Cartesian Therapeutics Recent Developments
9 Concluding Insights
10 Appendix
- 10.1 Reasons for Doing This Study
- 10.2 Research Methodology
- 10.3 Research Process
- 10.4 Authors List of This Report
- 10.5 Data Source
- 10.5.1 Secondary Sources
- 10.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
$4,250USD
Buy nowPDF by email within 3–5 working days after payment confirmation.
Talk to an analyst